At present, the use of ABL kinase inhibitors (e.g. imatinib) for the treatment of CML can inhibit the activity of BCR-ABL kinase effectively, inhibit the malignant proliferation of leukemia cells, and extend the survival time of patients significantly. The gene discussed is BCR; the disease is leukemia.